St John's wort works for moderate depression and is one of the most interacting substances in this handbook. Both facts are load-bearing.
Depression is common, treatable, and the treatment with the best evidence is not a herb. Psychological therapy and, where indicated, medication, have the outcome data — and this page exists because the opposite is often implied by the herbal industry.
St John's wort has the best trial evidence of any herb for depression. Pooled analyses in mild to moderate depression show effects comparable to standard antidepressants in some trials, with fewer side effects than SSRIs in several comparisons, though the trials are heterogeneous and the preparations vary enormously in hyperforin content. The interaction profile is the critical part: St John's wort induces CYP3A4, CYP2C19 and P-glycoprotein, and it measurably reduces blood levels of a long list of drugs. In a systematic review and meta-analysis it significantly decreased the exposure to midazolam, a probe for CYP3A4. The practical consequences include failure of hormonal contraception, reduced immunosuppressant levels with the risk of organ rejection, reduced antiretroviral levels, and reduced anticoagulant effect. It also causes serotonin syndrome in combination with SSRIs, triptans, tramadol and other serotonergic drugs. And it causes photosensitivity.
Saffron has small trials in depression showing effects over placebo, sometimes comparable to an SSRI at low dose. The trials are small and the product is expensive.
Omega-3 — pooled analyses show a small effect in depression, strongest for EPA-dominant preparations. The evidence is inconsistent.
Exercise has randomised evidence for depression, with effect sizes comparable to medication for mild to moderate depression in some trials. This is the strongest non-pharmacological recommendation on the page.
The safety framing is the most important part of this page. Depression can be severe, it can be fatal, and a person who is having suicidal thoughts needs help today, not a supplement trial. Anything that delays effective treatment — including a well-meaning suggestion to try an herb first — costs time that matters.
Meta-Analysis2025Molecular psychiatry
Nutraceuticals and phytoceuticals in the treatment of schizophrenia: a systematic review and network meta-analysis "Nutra NMA SCZ".
Further high-quality trials in acute phases/specific outcomes/difficult-to-treat schizophrenia are warranted.
PubMed 39026098 ↗
Meta-Analysis2025Nutrition reviews
Effect of Saffron Versus Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment of Depression and Anxiety: A Meta-analysis of Randomized Controlled Trials.
Saffron could be a potential SSRI alternative to reduce depressive and anxiety symptoms with fewer adverse events.
PubMed 38913392 ↗
Meta-Analysis2025Psychological medicine
Comparative efficacy and tolerability of nutraceuticals for depressive disorder: A systematic review and network meta-analysis.
This extensive systematic review and NMA of nutraceuticals for treating depressive disorders indicated a number of nutraceuticals that could offer benefits, either as adjuncts or monotherapies.
PubMed 40314175 ↗
Meta-Analysis2025International journal of mental health nursing
The Effects of Aerobic and Resistance Exercise on Depression and Anxiety: Systematic Review With Meta-Analysis.
Protocol Registration: PROSPERO registration number: CRD42019119341 (date of registration: 5/2/2019).
PubMed 40432290 ↗
Meta-Analysis2025JAMA network open
Exercise Interventions for Depression, Anxiety, and Quality of Life in Older Adults With Cancer: A Systematic Review and Meta-Analysis.
In this systematic review and meta-analysis of 27 RCTs, exercise interventions were found to be associated with significantly reduced levels of depression and anxiety and significantly improved HRQOL in older adults with cancer.
PubMed 39903465 ↗
Meta-Analysis2025British journal of sports medicine
Impact of postpartum physical activity on maternal depression and anxiety: a systematic review and meta-analysis.
Postpartum exercise reduced the severity of depressive and anxiety symptoms and the odds of postpartum depression.
PubMed 39500542 ↗